In ovarian cancer (SK-OV-3 and SK-OV-3/DDP) cells, apigenin reduces myeloid cell leukemia-1 (Mcl-1) mRNA and protein levels, a member of the anti-apoptotic Bcl-2 family, thereby reversing cisplatin resistance [32, 56, 57]. Here, BCL2 is linked to ovarian carcinoma.